Asia Healthcare in final talks to buy Nova IVI fertility

Asia Healthcare Holdings, the platform backed by global investors TPG Growth and Temasek Holdings, is all set to acquire Nova IVI Fertility, one of the largest operators of fertility clinics in India, in a deal said to be worth $100 million.

AHH will buy stakes from existing private equity investors and promoters including founder Mahesh Reddy, said two people aware of the development.

Goldman Sachs Group Inc and New Enterprise Associates together hold about 51% in Nova IVI, New York-based fund GTI Group has about 15% and the promoters the remainder. Investment bank Lincoln International is managing the sale, which is expected to be signed in a couple of weeks, said one person.

Nova IVI Fertility was formed in 2012 when Nova Pulse IVF, a division of Nova Medical Centers, formed a technical partnership with IVI, a Spanish chain of IVF clinics, and now operates 20 fertility centres in 15 Indian cities. Nova Medical Centers was founded by GTI Group and Reddy in 2009.

Spokespersons at Temasek, TPG and Goldman Sachs declined to comment. Mails sent to New Enterprise Associates, GTI Capital and Nova IVI spokespersons did not elicit any response until press time.

Nova IVI provides assisted-reproductive therapy treatments such as intrauterine insemination (IUI), in vitro fertilisation (IVF) and andrology services.

About 10-15% of married couples in India and almost 27.5 million couples who are actively seeking children suffer from infertility, according to a report by advisory firm EY. The key risk factors leading to a high prevalence of infertility include increasing marital age, growing number of working women and rising alcohol and tobacco consumption.

AHH’s portfolio currently consists of Cancer Treatment Services International, a network of single-specialty cancer hospitals across South Asia also known as American Oncology Institute, and Bengaluru-based Rhea Healthcare, which operates a network of hospitals for women and children under the ‘Motherhood’ brand. After partnering with AHH, CTSI has expanded to seven facilities from a single one, while the Motherhood network has grown to 11 hospitals from three.

Focusing on India and South Asia, AHH invests in single-specialty healthcare businesses. Sheares Healthcare, owned by Temasek, invested $50 million in AHH in July to acquire a minority stake. AHH is led by Vishal Bali, senior healthcare advisor at TPG Growth and former CEO at Fortis Healthcare and Wockhardt Hospitals.

About 75% of India’s IVF market is controlled by the top 500 clinics and the rest are held by unorganised entities.

The main IVF service providers in India include Indira IVF, Southend Fertility & IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Nova IVI Fertility, Ridge IVF, Akanksha IVF, Bourn Hall Clinic and Jaipur-based Shivani Fertility and Mother Care.

  • Related Posts

    All the Way from Teeth to Tee: Hole in One

    6th Edition of All India Dental Fraternity Invitation Golf Tournament in Class & Style Manesar/ New Delhi: Dentistry is now a high- end domain with class and style.  6th Edition…

    Will ‘Epidemic’ of Bridge Collapse in Bihar halt with new Minister in?

    Hope floats for good ‘Health’ of Bridges, Flyovers & Roads in the state Patna/ New Delhi: Talking of bridges, roads and flyovers in terms of ‘health’ may sound a bit…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states

    All the Way from Teeth to Tee: Hole in One

    All the Way from Teeth to Tee: Hole in One

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Chemists strike on May 20: Reasons behind today’s all-India strike

    Chemists strike on May 20: Reasons behind today’s all-India strike

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug